Eliquis and Retinal vascular disorder - a phase IV clinical study of FDA data

Summary:

Retinal vascular disorder is found among people who take Eliquis, especially for people who are male, 60+ old.

The phase IV clinical study analyzes which people take Eliquis and have Retinal vascular disorder. It is created by eHealthMe based on reports of 142,078 people who have side effects when taking Eliquis from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

142,078 people reported to have side effects when taking Eliquis.
Among them, 6 people (0.0%) have Retinal vascular disorder.


What is Eliquis?

Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 143,649 Eliquis users for its effectiveness, alternative drugs and more.

What is Retinal vascular disorder?

Retinal vascular disorder (a range of eye diseases that affect the blood vessels in the eye) is found to be associated with 310 drugs and 174 conditions by eHealthMe.

Number of Eliquis and Retinal vascular disorder reports submitted per year:

Could Eliquis cause Retinal vascular disorder?

Gender of people who have Retinal vascular disorder when taking Eliquis *:

  • female: 33.33 %
  • male: 66.67 %

Age of people who have Retinal vascular disorder when taking Eliquis *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Eliquis *:

  1. Zetia: 1 person, 16.67%
  2. Vitamin D: 1 person, 16.67%
  3. Tylenol: 1 person, 16.67%
  4. Revlimid: 1 person, 16.67%
  5. Prochlorperazine: 1 person, 16.67%
  6. Nitrostat: 1 person, 16.67%
  7. Morphine Sulfate: 1 person, 16.67%
  8. Metoprolol Succinate: 1 person, 16.67%
  9. Lipitor: 1 person, 16.67%
  10. Lasix: 1 person, 16.67%

Common side effects people have besides Retinal vascular disorder *:

  1. Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 16.67%
  2. Retinal Haemorrhage (bleeding from retina): 1 person, 16.67%
  3. Amaurosis (partial or total blindness without visible change in the eye): 1 person, 16.67%

Common conditions people have *:

  1. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 33.33%
  2. Pain: 1 person, 16.67%
  3. Multiple Myeloma (cancer of the plasma cells): 1 person, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Eliquis and have Retinal vascular disorder?

Check whether Retinal vascular disorder is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Retinal vascular disorder and when was it recovered:

Expand to all the drugs that have ingredients of apixaban:

Alternative drugs to, pros and cons of Eliquis:

Common Eliquis side effects:

Browse all side effects of Eliquis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Retinal vascular disorder treatments and more:

COVID vaccines that are related to Retinal vascular disorder:

All the drugs that are associated with Retinal vascular disorder:

All the conditions that are associated with Retinal vascular disorder:

How the study uses the data?

The study uses data from the FDA. It is based on apixaban (the active ingredients of Eliquis) and Eliquis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: